Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease
- PMID: 39999620
- PMCID: PMC11903820
- DOI: 10.1016/j.bjid.2025.104517
Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease
Abstract
Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
Keywords: Antifungal agents; Hematologic neoplasms; Invasive pulmonary aspergillosis; Latin America.
Copyright © 2025 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.
Conflict of interest statement
Conflicts of interest The following authors declared no conflict of interest: DAR, DC, DCN, LCN, CD, SIC, LEC, BLG, AMCR, DLO. The following authors declared conflict of interest: JAC (Pfizer), MCV (Pfizer), RMR (Gilead Sciences, Gador, Pfizer), CAA (Moderna, Merck Sharp & Dohme, GlaxoSmithKline, Becton Dickinson, Pfizer), MN (Pfizer, Merck Sharp & Dohme, Knight Therapeutics), LT (Gador, Gilead Sciences, Knight Therapeutics), DEC (IMMY), EPV (Pfizer), FR (Gador, Gilead Sciences, Knight Therapeutics), PC (Pfizer, Merck Sharp & Dohme), RAR (Pfizer, SteinCares, Merck Sharp & Dohme). With no stated interests identified that could be considered potentially conflicting with the primary interest of this EBCS.
Figures




Similar articles
-
Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia.BMC Infect Dis. 2015 Jul 1;15:251. doi: 10.1186/s12879-015-0995-8. BMC Infect Dis. 2015. PMID: 26126706 Free PMC article.
-
Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?J Infect. 2012 Sep;65(3):262-8. doi: 10.1016/j.jinf.2012.05.001. Epub 2012 May 9. J Infect. 2012. PMID: 22580034 Free PMC article.
-
Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes.Ann Med. 2018 Dec;50(8):713-720. doi: 10.1080/07853890.2018.1518581. Epub 2018 Sep 29. Ann Med. 2018. PMID: 30230385
-
Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis.Med Mycol. 2009;47 Suppl 1:S291-8. doi: 10.1080/13693780802510232. Epub 2009 Mar 21. Med Mycol. 2009. PMID: 19306226 Review.
-
Current treatment options for invasive aspergillosis.Drugs Today (Barc). 2013 Mar;49(3):213-26. doi: 10.1358/dot.2013.49.3.1921234. Drugs Today (Barc). 2013. PMID: 23527325 Review.
References
-
- Cadena J., Thompson G.R., Patterson T.F. Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin North Am. 2016;30:125–142. 3rd. - PubMed
-
- Pagano L., Akova M., Dimopoulos G., Herbrecht R., Drgona L., Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5–14. - PubMed
-
- Thompson G.R., Young J.H. Aspergillus infections. N Engl J Med. 2021;385:1496–1509. 3rd. - PubMed
-
- Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347. - PubMed
-
- Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous